| Clinical data | |
|---|---|
| Other names | DAM-57;N,N-Dimethyllysergamide; DAM; Lysergic acid dimethylamide |
| Routes of administration | Oral[1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H21N3O |
| Molar mass | 295.386 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
DAM-57, also known asN,N-dimethyllysergamide (DAM) or aslysergic acid dimethylamide, is aderivative ofergine. There has been a single report of observing N,N-dimethyl-D-lysergamide in the illicit drug market.[2] This compound did induce autonomic disturbances at oral levels of some 10 times the dose required forlysergic acid diethylamide (LSD), presumably in the high hundreds of micrograms. There is some disagreement as to whether there were psychic changes observed.[1] It was first described in thescientific literature byAlbert Hofmann and colleagues by 1955.[3]
Thishallucinogen-related article is astub. You can help Wikipedia byexpanding it. |